PILA PHARMA AB has announced that February 15, 2026, is the final day for exercising warrants of series TO2, which allow holders to subscribe for two new shares in the company at a price of SEK 1.50 per share. If fully exercised, the company could raise approximately SEK 44.87 million before costs. Holders must actively subscribe for new shares to prevent the warrants from expiring without value. The exercise period runs from February 5 to February 15, 2026, but some platforms may close applications earlier. The full terms and a prospectus approved by the Swedish Financial Supervisory Authority are available on the company's website. The exercise outcome will be announced around February 16, 2026. PILA PHARMA, a Swedish biotech company, focuses on developing TRPV1 inhibitors for treating obesity, type 2 diabetes, and other inflammatory-related diseases. Their candidate, XEN-D0501, has shown promise in clinical trials and is moving towards further studies. The company also explores licensing opportunities for erythromelalgia and other conditions. The press release includes legal disclaimers and information for distributors regarding the investment's risks and target market.

PILA PHARMA AB, a Swedish biotech company focused on developing novel oral drugs based on TRPV1 inhibition, hosted a live online interview and Q&A session with CEO Gustav H. Gram on February 10, 2026, in collaboration with Infront Direkt Studios. The session, which can be replayed online, was held in conjunction with the release of the company's H2/Year-end report. During the interview, Gram discussed the company's financial status, recent preclinical studies, the ongoing TO2 warrant period, future clinical plans for obesity treatment, and clinical preparations for erythromelalgia. PILA PHARMA, listed on Nasdaq First North Growth Market, is advancing the development of XEN-D0501, a TRPV1 inhibitor, for treating obesity, type 2 diabetes, and potentially other inflammatory diseases. The company has completed two phase 2a clinical trials demonstrating the drug's tolerability and effectiveness in enhancing insulin response. A clinical trial application for a dose-finding study in obesity is planned for submission by the end of Q1 2026. Additionally, PILA PHARMA is exploring licensing opportunities for erythromelalgia and abdominal aorta aneurysm treatments. The company aims to address the global obesity and diabetes pandemics, which have significant health impacts and economic costs. Erythromelalgia, a rare disease with no current treatments, is also a focus for future development.

PILA PHARMA AB, a Swedish biotech company focused on developing TRPV1 inhibitors for obesity, type 2 diabetes, and other inflammatory diseases, will host a live online interview and Q&A session on February 10, 2026. The event, featuring CEO Gustav H. Gram, coincides with the release of the company's H2/Year-end report. Key topics include the company's cash position, recent preclinical studies, the TO2 warrant period, future clinical plans for obesity, and clinical preparations for erythromelalgia. Attendees can submit questions via email or chat, and the session will be available for later viewing. PILA PHARMA, listed on Nasdaq First North Growth Market, is advancing its drug candidate XEN-D0501, which has shown promise in clinical trials for obesity and type 2 diabetes. The company is preparing a clinical trial application for a dose-finding study in obesity by Q1 2026. Additionally, PILA PHARMA holds patents for TRPV1-antagonists and seeks licensing opportunities for erythromelalgia and other conditions. Obesity and diabetes are major global health concerns, with significant unmet needs for effective treatments. Erythromelalgia, a rare disease causing severe pain and inflammation, lacks current treatments, and PILA PHARMA is developing a clinical plan for this condition.

PILA PHARMA AB, a biotech company, is preparing a clinical trial application for a proof-of-concept study to develop its oral TRPV1 inhibitor as a treatment for erythromelalgia, a rare disease characterized by neurogenic inflammation and severe pain. The company received orphan drug designation from the FDA in 2022 and plans to conduct a smaller study to demonstrate the drug's efficacy before proceeding to phase 2/3 trials. The expected time to market is approximately three years, with potential regulatory exclusivity of seven years in the US post-approval. Erythromelalgia can cause debilitating pain, affecting quality of life and potentially increasing mortality and suicide rates. PILA PHARMA's founder expressed optimism about the drug's potential to alleviate pain and improve patients' lives. The company's scientific expert highlighted the benefits of the drug's tablet form, which could also prevent pain attacks. PILA PHARMA, based in Malmö, Sweden, focuses on developing TRPV1 inhibitors for obesity, type 2 diabetes, and other inflammatory diseases. The company has completed two phase 2a trials showing XEN-D0501's tolerability in obesity and diabetes patients. They plan to submit a clinical trial application for a dose-finding study in obesity by Q1 2026. Erythromelalgia currently lacks approved treatments, and PILA PHARMA aims to provide a systemic oral solution.

PILA PHARMA AB, a Swedish biotech company, announced it will release its interim report for the second half of 2025 on February 10, 2026, earlier than the initially planned date of February 26, 2026. The change is due to the report's early completion and to facilitate the Board of Directors' and CEO's warrant exercises. PILA PHARMA, based in Malmö, focuses on developing TRPV1 inhibitors for treating obesity, type 2 diabetes, and other inflammatory diseases. Their lead candidate, XEN-D0501, has shown promise in clinical trials, demonstrating good tolerability and efficacy in enhancing insulin response in diabetic patients. The company plans to submit a clinical trial application for a dose-finding study in obese patients by the end of Q1 2026. Additionally, PILA PHARMA is exploring licensing opportunities for XEN-D0501 in treating erythromelalgia, a rare inflammatory disease. The company aims to address the growing demand for effective oral treatments for obesity and diabetes, which are global health concerns.

PILA PHARMA AB, a biotech company focused on developing a TRPV1 inhibitor, completed a rights issue of units, including shares and warrants, in the third quarter of 2025. Each warrant allows the holder to subscribe for two new shares at a price set at SEK 1.50, determined as 70% of the average market price, with an exercise period from February 5 to February 15, 2026. If all warrants are exercised, PILA PHARMA could raise approximately SEK 44.87 million before costs. The company's main project, XEN-D0501, targets obesity and type 2 diabetes, with plans to submit a clinical trial application by the end of Q1 2026. The company also explores licensing opportunities for treating erythromelalgia. PILA PHARMA's shares are traded on Nasdaq First North Growth Market, Sweden.

PILA PHARMA AB is a Swedish biotech company focusing on developing TRPV1 inhibitors as treatments for obesity, type 2 diabetes, and other inflammatory diseases. The company is hosting an online Q&A session on January 27, 2026, to discuss its preclinical studies and upcoming clinical activities. CEO Gustav H. Gram and Founder Dorte X. Gram will represent the company. PILA PHARMA's drug candidate, XEN-D0501, has shown promise in clinical trials for obesity and diabetes, demonstrating good safety and efficacy. The company plans to submit a clinical trial application for a dose-finding study in obesity by the end of Q1 2026. Obesity and diabetes are global health challenges with significant unmet needs, and PILA PHARMA aims to provide effective oral treatments. The company also holds patents for TRPV1 inhibitors and is exploring licensing opportunities for erythromelalgia and abdominal aorta aneurysm treatments.

PILA PHARMA AB, a Swedish biotech company, announced an agreement with a new clinical Contract Research Organisation to prepare a clinical trial application for obesity treatment, expected to be submitted by the end of Q1 2026. The company completed preclinical studies in rat obesity with inconclusive results, as the formulation used may have affected drug absorption. PILA PHARMA plans to proceed with a clinical dose-finding study for obesity in collaboration with the new CRO. The company's CEO highlighted a successful fundraising effort that allows for accelerating the study. PILA PHARMA focuses on developing TRPV1 inhibitors for obesity and type 2 diabetes, and aims to submit further patents related to its drug candidate XEN-D0501. The company has previously completed two clinical trials showing XEN-D0501's tolerability and efficacy in enhancing insulin response. Additionally, PILA PHARMA holds an orphan drug designation for treating erythromelalgia, a rare disease, and seeks licensing opportunities for this and other conditions.

PILA PHARMA AB, a Swedish biotech company, is developing a novel oral drug, XEN-D0501, based on TRPV1 inhibition for treating obesity and diabetes. The company's CEO, Gustav Hanghøj Gram, appeared on the Market Makers podcast to discuss the company's history, its drug development aspirations, and the potential impact of their oral solution in the obesity market. The obesity market is significant, with over 1 billion people globally, and PILA PHARMA aims to address this with their innovative treatment. XEN-D0501 has shown promise in clinical trials, demonstrating safety and efficacy in enhancing insulin response and reducing cardiovascular risk markers. The company is preparing for further clinical trials to assess the drug's maximal tolerable dose and its effectiveness in reducing body weight. Additionally, PILA PHARMA is exploring licensing opportunities for treating Erythromelalgia and Abdominal Aorta Aneurysm, with XEN-D0501 showing potential benefits in preclinical studies for these conditions. The company is focused on creating a comprehensive data package to support XEN-D0501 as a first-in-class oral drug candidate for obesity and diabetes.

PILA PHARMA AB, a Swedish biotech company, is advancing its investor relations by initiating research coverage with Analyst Group. This includes quarterly equity research updates and analyst comments on financial reports. PILA PHARMA is developing XEN-D0501, a TRPV1 inhibitor, as a treatment for obesity and diabetes. The drug is noted for its potential distinct side-effect profile and simpler synthesis compared to current therapies. The company has completed two phase 2a trials showing the drug's tolerability and efficacy in enhancing insulin response. A new trial, PP-CT03, aims to determine the maximal tolerable dose and assess safety over three months. PILA PHARMA is also exploring licensing opportunities for Erythromelalgia and Abdominal Aorta Aneurysm, with preclinical success in reducing aneurysm growth. The company seeks to expand its visibility in Nordic capital markets through collaborations like the one with Analyst Group.

PILA PHARMA AB, a Swedish biotech company, is developing an oral drug, XEN-D0501, as a TRPV1 inhibitor for obesity and diabetes treatment. The company has been invited to present at the Biotech Showcase during the 2026 J.P. Morgan Healthcare week in San Francisco. CEO Gustav H. Gram will discuss their approach to obesity treatment with American investors. XEN-D0501 is noted for its potential safety and manufacturing advantages over existing treatments. The drug has shown promise in clinical trials, improving insulin response and reducing cardiovascular biomarkers. PILA PHARMA holds patents for TRPV1 antagonists in obesity and diabetes treatment and is pursuing further development and licensing opportunities in related fields, including erythromelalgia and abdominal aorta aneurysm. The global prevalence of obesity and diabetes underscores the demand for innovative treatments like XEN-D0501.

PILA PHARMA AB, a Swedish biotech company focused on developing TRPV1 inhibitors for treating obesity and diabetes, announced that CEO Gustav H. Gram has increased his shareholding by acquiring 40,188 shares at an average price of SEK 2.15 each. Gram now holds 207,484 shares. The purchase was reported to the Swedish Financial Supervisory Authority. PILA PHARMA is advancing its drug candidate XEN-D0501, which has shown promise in clinical trials for obesity and type 2 diabetes, and is preparing for further trials to assess its efficacy and safety. The company also explores licensing opportunities for treating conditions like Erythromelalgia and Abdominal Aorta Aneurysm, where XEN-D0501 has shown potential benefits.